UBE2D2

Across TCGA pan-cancer cohorts, UBE2D2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of UBE2D2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where UBE2D2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types UBE2D2 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

CCRCC and COAD are the cancer types where UBE2D2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in UBE2D2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.475	<.001	11	view →
COAD	Male	II,III,IV	−0.981	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

UBE2D2–CCRCC

Open the CCRCC breakdown →